Evidence map›Paper›PMID 30134556›Full record

ArticleInternational journal of molecular sciences2018

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Julia Chudzian, Anna Szlachcic, Malgorzata Zakrzewska, Miroslawa Czub, Marcin Pustula, Tad A Holak, Jacek Otlewski

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Julia ChudzianDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14A, 50-383 Wroclaw, Poland. julia.chudzian@uwr.edu.pl.
Anna SzlachcicDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14A, 50-383 Wroclaw, Poland. anna.szlachcic@uwr.edu.pl.
Malgorzata ZakrzewskaDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14A, 50-383 Wroclaw, Poland. malgorzata.zakrzewska@uwr.edu.pl.
Miroslawa CzubFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland. miroslawa.luty@gmail.com.
Marcin PustulaFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland. pustula.marcin@gmail.com.ORCID 0000-0001-6790-5670
Tad A HolakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland. holak@chemia.uj.edu.pl.
Jacek OtlewskiDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14A, 50-383 Wroclaw, Poland. jacek.otlewski@uwr.edu.pl.ORCID 0000-0001-8630-2891
University of Wrocław · PLJagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor types, including lung or breast cancer. The development of FGF1-targeting molecules with potential implications for the therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment of cancer. In this study we have used phage display selection to find scFv antibody fragments selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones were expressed and characterized with regard to their binding to FGF1 and ability to interfere with FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format, as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective cancer therapy.

Indexed as

Peptide LibraryAnimalsCell Line, TumorCell ProliferationClone CellsCloning, MolecularCross ReactionsEscherichia coliFibroblast Growth Factor 1Gene ExpressionGenetic VectorsHumansKineticsMiceNIH 3T3 CellsProtein BindingFibroblast Growth Factor 1Peptide LibraryReceptor, Fibroblast Growth Factor, Type 1Recombinant Fusion ProteinsSingle-Chain AntibodiesFGF1FGFRgrowth factor receptor targetingligand trapphage displayscFv antibody fragmentsscFv-Fc fusionstumor targeting treatment

Identifiers

PMID30134556
PMCPMC6163658
OpenAlexW2888351587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.